July 2023 in “Journal of Clinical Medicine” This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.
September 2025 in “Cureus” This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.
June 2026 in “Dermatology and Therapy” In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.
37 citations
,
March 2006 in “Regulatory Peptides” This study reports that GLP-1 receptors and proglucagon are expressed in the skin of newborn mice, with GLP-1 potentially playing a role in skin development and hair follicle formation.
27 citations
,
December 2013 in “Endocrinology” This study established a mouse model for Cushing's syndrome due to a specific Crh mutation, which may help explore the effects of glucocorticoid excess and evaluate treatments for corticosteroid-induced osteoporosis.